Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

Table 1

Patient characteristics (n = 991).

Age (years)	65.8 (56.3–74.9) [26.7–98.7]
Sex
Female	244 (24.6%)
Male	747 (75.4%)
Hypertension	430 (43.4%)
Hypercholesterolemia	308 (31.1%)
Diabetes mellitus	144 (14.5%)
Prior myocardial infarction	98 (9.9%)
Prior PCI	132 (13.3%)
Prior CABG	50 (5.0%)
Prior ischemic stroke or TIA	40 (4.0%)
Prior intracranial bleeding	10 (1.0%)
LVEF (%)	47 (40–55) [5–70]
Plasma creatinine (μmol/l)	75 (63–92) [31–787]
Blood haemoglobin (mmol/l)	8.3 (7.7–9.0) [3.4–13.0]
Platelet count (10^9/l)	235 (199–278) [43–723]

PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack; LVEF: left ventricular ejection fraction; eGFR: estimated glomerular filtration rate. Age, LVEF, plasma creatinine, blood haemoglobin, and blood thrombocytes are reported as median (quartiles) [range]. Other variables are reported as count (percent).